Michael Lefenfeld is President and Chief Executive Officer at Hexion Inc. and serves as a member of the Board of Managers for ASP Resins Holdings LP. 

Michael joined Hexion in January 2023. Prior to joining Hexion and beginning in 2018, Michael served as President and CEO of Cyanco International, where he led the world’s largest manufacturer of gold and silver extraction materials, while driving the effort to make recovery safer and more efficient. From 2007 to 2017, he was President and CEO of SIGNa Chemistry, a global chemical manufacturer of reactive metal materials serving oil & gas recovery, petrochemical refining, alternative energy and chemical processing industries. Michael also founded Alkami Consulting Group, a technology investment advisory group, and Blood Gas Diagnostics, a medical device technology growth company. 

Lefenfeld built his career around the belief that many of the solutions our world seeks — better healthcare, cleaner manufacturing, and sustainable energy — can be achieved with better science. He has dedicated his career to cutting-edge scientific research and his work has led to safer industrial environments, better medical technologies, and more effective, affordable energy solutions. Prior to SiGNa, Lefenfeld embraced his ability for developing and commercializing new technology and launched and sold three other companies by the time he was 30. He has been widely recognized for his efforts including: World Economic Forum Young Global Leader, ICIS Top Chemical Power Player to Watch, Cedars-Sinai Award for Technology Innovation in Medical Devices, Red Herring Magazine’s Top 25 Entrepreneurs Under 35, Inc. Magazine’s Top 30 Entrepreneurs Under 30, BusinessWeek’s Best Entrepreneurs Under 25. He also holds more than 50 patents in areas including medical devices, controlled release, electronics, chemical reactivity and information technology.

Lefenfeld has a Master of Philosophy in Chemistry from Columbia University and a bachelor's degree in chemical engineering from Washington University in St. Louis. Lefenfeld is an annual lecturer at UC Berkeley’s Haas School of Business and is an adjunct faculty scholar at Michigan State University. He is a member of the business advisory board for the Alzheimer's Drug Discovery Foundation, the board of entrepreneurs for Venture for America, the board of directors for the Juvenile Diabetes Research Foundation (NYC Chapter) and the advisory board for Washington University of St. Louis’ EECE.